Supreme Court Patent Ruling Will Have Little Impact on Our Gene Innovators
As you've probably heard, the U.S. Supreme Court unanimously ruled that naturally occurring human genes cannot be patented. I've been getting some questions on the impact of this ruling. The case was brought against Myriad Genetics, which claimed a patent on the BRCA1 and BRCA2 genes. Mutations in these genes are important markers for breast cancer risk and were used in Myriad's diagnostic tests. Others sued Myriad because they wanted the right to use these genes in their own tests.
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Technology Profits Confidential
With new technologies in mobile computing, biotechnology and 3-D printing, it’s nearly impossible to keep up with the throngs of new innovation and still be able to forecast which companies are set to profit. Technology Profits Confidential is your one-stop shop for the companies of tomorrow’s technology… and how you can profit from them.